Detailed view for LdBPK_240220.1

Basic information

TDR Targets ID: 817112
Leishmania donovani, protein kinase, putative
Source Database / ID: 

pI: 6.0332 | Length (AA): 543 | MW (Da): 57987 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00069   Protein kinase domain
PF00498   FHA domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0005524   ATP binding  
GO:0005515   protein binding  
GO:0004672   protein kinase activity  
GO:0006468   protein amino acid phosphorylation  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 6 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
40 167 2kkl (A) 25 145 25.00 0 1 0.424927 -0.03
55 165 1qu5 (A) 560 684 21.00 0.00041 0.48 0.33542 -0.51
85 514 5dyk (A) 423 806 21.00 0 1 0.716897 1.17
92 167 1r21 (A) 23 96 22.00 0.0024 0.51 0.457963 -1.15
102 167 2ff4 (A) 313 377 26.00 0 0.33 0.330747 -0.35
201 506 2jbp (J) 69 325 42.00 0 1 0.370136 1.08

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

No expression data available for this gene

Orthologs

Ortholog group members (OG5_183634)

Species Accession Gene Product
Leishmania braziliensis LbrM.24.0220   protein kinase, putative
Leishmania donovani LdBPK_240220.1   protein kinase, putative
Leishmania infantum LinJ.24.0220   protein kinase, putative
Leishmania major LmjF.24.0230   protein kinase, putative
Leishmania mexicana LmxM.24.0230   protein kinase, putative

Essentiality

No essentiality data collected for this gene and/or its orthologs.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
Species Target Length Identity Alignment span Linked Drugs Reference
Plasmodium falciparum (isolate 3D7) Cell division control protein 2 homolog 288 aa 21.7% 300 aa Compounds References
Rattus norvegicus Mitogen-activated protein kinase 1 358 aa 18.8% 330 aa Compounds References
Rattus norvegicus c-Jun N-terminal kinase 3 464 aa 21.8% 390 aa Compounds References
Sus scrofa Glycogen synthase kinase 3 beta 420 aa 24.4% 353 aa Compounds References
Xenopus laevis Aurora kinase B-A 361 aa 24.8% 319 aa Compounds References
Homo sapiens Cyclin-dependent kinase 1/cyclin B1 297 aa 23.3% 317 aa Compounds References
Bos taurus Glycogen synthase kinase-3 beta splice variant X1 419 aa 24.4% 348 aa Compounds References
Rattus norvegicus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 25.6% 316 aa Compounds References
Patiria pectinifera Cdc2 300 aa 22.3% 341 aa Compounds References
Xenopus laevis Aurora kinase B-B 368 aa 24.8% 319 aa Compounds References
Rattus norvegicus Mitogen-activated protein kinase 8 411 aa 20.8% 380 aa Compounds References
Oryctolagus cuniculus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 25.2% 326 aa Compounds References
Rattus norvegicus Glycogen synthase kinase-3 beta 420 aa 24.1% 348 aa Compounds References
Rattus norvegicus Serine/threonine-protein kinase pim-3 326 aa 27.0% 322 aa Compounds References
Bos taurus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 25.8% 325 aa Compounds References
Rattus norvegicus Cell division protein kinase 5 292 aa 24.7% 324 aa Compounds References
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LdBPK_240220.1 (Leishmania donovani), protein kinase, putative
Title for this comment
Comment